Abstracts Archive - Page 439 of 2607 - ACR Meeting Abstracts

Abstract Number: 1721 • ACR Convergence 2023
The Therapeutic Effects of Gingival Mesenchymal Stem Cells and Their Exosomes in a Chimeric Model of Rheumatoid Arthritis
shane Bruckner¹, Braden Zeno², Vittoria Capria¹, William Willis³, Latha Prabha Ganesan¹ and wael Jarjour¹, ¹Ohio State University, Columbus, OH, ²Ohio State University, Upper Arlington, OH, ³Ohio State University, Reynoldsburg, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction involving multiple joints. There is a large body of…
Abstract Number: 2152 • ACR Convergence 2023
Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study
Xinjia Deng¹, Yuqing Zhang², Yilun Wang¹, Na Lu³, Dongxing Xie⁴, Houchen Lyu⁵, Jie Wei⁶, Chao Zeng¹, Guanghua Lei¹ and Hui Li¹, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Xiangya Hospital, Central South University, Changsha, China, ⁵Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, ⁶Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and mortality. Many patients with RA underwent knee and…
Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 1732 • ACR Convergence 2023
Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)
Huiyi Wang¹, Kangkang Luo¹, Shuxin Xu¹, Jiayin Zhou¹, Santi Chen², Jun wang², Wenzhao Li², Jing Zhao¹ and Cunxiang Ju¹, ¹GemPharmatech CO., Ltd., Nanjing, China, ²GemPharmatech LLC, La Jolla, CA
Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research…
Abstract Number: 2149 • ACR Convergence 2023
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Yuriko Yamamura¹, Kieran Woolcock², Valerie Corrigall³, Lara Ravanetti⁴, Jorge De Alba⁴, Roly Foulkes⁵, Paul Eggleton⁶ and Carl Goodyear², ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Revolo Biotherapeutics, Tadworth, United Kingdom, ⁴Revolo Biotherapeutics, London, United Kingdom, ⁵Revolo Biotherapeutics, Slough, United Kingdom, ⁶Revolo Biotherapeutics, Exeter, United Kingdom
Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1723 • ACR Convergence 2023
3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity
Brendan Allen¹, Sabrina Fechtner², Meagan Chriswell³, Widian Jubair¹, M. Aaron Vrolijk¹, V. Michael Holers⁴ and kristine Kuhn¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz SOM, Denver, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
Abstract Number: 1743 • ACR Convergence 2023
Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle³, kevin Deane³, Michael Holer³ and kristine Kuhn², ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
Abstract Number: 1727 • ACR Convergence 2023
Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
Abstract Number: 1736 • ACR Convergence 2023
The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis
Patricia Riedlova¹, Kieran Woolcock², Cecilia Ansalone² and Carl Goodyear², ¹University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Osteoclasts (OCs) are multinucleated bone-resorbing cells playing a key role in rheumatoid arthritis (RA). Under physiological conditions, OCs are in balance with bone-forming osteoblasts,…
Abstract Number: 1537 • ACR Convergence 2023
Long-term Observational Study of Interstitial Lung Disease in ANCA-associated Vasculitis
aglaia chalkia¹, Dr Rachel Jones², Pasupathy Sivasothy³ and David Jayne⁴, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: There is limited data on the epidemiology and long-term outcome of patients with Interstitial Lung Disease (ILD) in ANCA-associated Vasculitis (AAV) with conflicting results…
Abstract Number: 1549 • ACR Convergence 2023
Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, immune-inflammatory disorder characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation, and chronic necrotizing vasculitis of small-to-medium-sized blood…
Abstract Number: 1127 • ACR Convergence 2023
Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Maria Paula Alvarez Hernandez¹, Inés Pérez Sancristóbal¹, Alfredo Madrid García², Lara Borrego Sanz³, Cristina Hormigos martín¹, Beatriz García Tirado³, Mayte Ariño Gutiérrez³, Cristina lajas Petisco¹, Pedro Arriola Villalobos³, Esperanza Pato Cour³ and Luis Rodríguez Rodríguez¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIU) are characterized by inflammation of the middle layer of the eye wall and have a significant impact on patients' visual-related quality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].